509 top medical experts on Hairy Cell Leukemia across 42 countries and 25 U.S. states, including 403 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.
- Hairy Cell Leukemia: A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
- Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
- Broader Categories (#Experts): Leukemia (4,683), Lymphoproliferative Disorders (2,703).
- Clinical Trials : at least 96 including 10 Active, 46 Completed, 17 Recruiting
- Synonyms: Leukemic Reticuloendotheliosis, Leukemic Reticuloendotheliosis
- Grever, Michael R HematologyDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA. . Top HospitalMedical school: University of Pittsburgh School of Medicine (MD, 1971)Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 82.3/100Subjects: Leukemia, Hairy Cell; Antineoplastic Agents; Pentostatin; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; CladribineCategories: Therapeutic Use; Drug Therapy; Administration & Dosage; Adverse Effects; Therapy; Diagnosis
- Andritsos, Leslie A HematologyDivision of Hematology Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.Medical school: University of Texas Medical Branch at Galveston (MD, 1999)Medicare AcceptedDisclosed payments from biomedical company (BeiGene USA, Inc.) in 2021 for $20.77Subjects: Leukemia, Hairy Cell; Antineoplastic Agents; Pentostatin; Protein Kinase Inhibitors; Cladribine; Drug EruptionsCategories: Therapeutic Use; Drug Therapy; Adverse Effects; Administration & Dosage; Etiology; Complications
- Park, Jae H Hematology & OncologyLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Top HospitalDisclosed payments in 2021 from 9 biomedical companies, totalling $21,788, including $10,980 from Kite Pharma, Inc.Subjects: Leukemia, Hairy Cell; Proto-Oncogene Proteins B-raf; Antineoplastic Agents; Cladribine; Indoles; MutationCategories: Therapeutic Use; Drug Therapy; Epidemiology; Genetics; Administration & Dosage; Diagnosis
- Saven, Alan Hematology & OncologyDivision of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA.Disclosed payments in 2021 from 32 biomedical companies, totalling $44,483.46, including $14,411.59 from Dova PharmaceuticalsSubjects: Leukemia, Hairy Cell; Antineoplastic Agents; Cladribine; Neoplasms, Second Primary; Pentostatin; Proto-Oncogene Proteins B-rafCategories: Therapeutic Use; Drug Therapy; Administration & Dosage; Adverse Effects; Epidemiology; Etiology
- Lozanski, Gerard Anatomic Pathology & Clinical PathologyDepartment of Pathology, The Ohio State University Medical Center, Columbus, OH, USA. Top HospitalDisclosed payments in 2021 from 2 biomedical companies, totalling $1,218.65, including $1,218.65 from F. Hoffmann-La Roche AGSubjects: Leukemia, Hairy Cell; Antineoplastic Agents; Pentostatin; Protein Kinase Inhibitors; Adenine; COVID-19Categories: Therapeutic Use; Drug Therapy; Genetics; Administration & Dosage; Analogs & Derivatives; Complications
- Blachly, James S HematologyDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA. Top HospitalDisclosed payments in 2021 from 2 biomedical companies, totalling $7,302.5, including $4,200 from Innate Pharma, IncSubjects: Leukemia, Hairy Cell; Antineoplastic Agents; Protein Kinase Inhibitors; Infections; Pentostatin; AdenineCategories: Therapeutic Use; Drug Therapy; Adverse Effects; Complications; Diagnosis; Etiology
- Kraut, Eric H HematologyDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA. Top HospitalDisclosed payments in 2021 from 2 biomedical companies, totalling $4,256.49, including $4,256.49 from Global Blood Therapeutics, Inc.Subjects: Leukemia, Hairy Cell; Antineoplastic Agents; Pentostatin; Antibodies, Monoclonal, Murine-Derived; COVID-19; CladribineCategories: Therapeutic Use; Drug Therapy; Complications; Pharmacology; Diagnosis; Etiology
- Rogers, Kerry A HematologyDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA. Top HospitalDisclosed payments in 2021 from 14 biomedical companies, totalling $13,595.87, including $4,798.74 from AbbVie Inc.Subjects: Leukemia, Hairy Cell; Protein Kinase Inhibitors; Adenine; Antineoplastic Agents; COVID-19; Genes, Immunoglobulin Heavy ChainCategories: Adverse Effects; Therapeutic Use; Complications; Drug Therapy; Etiology; Genetics
- Rai, Kanti R Hematology & OncologyDepartment of Medicine, Hofstra North Shore-Long Island Jewish School of Medicine, Hofstra University, Hempstead, NY.Medical school: Other (MD, 1955)Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 88.9/100Subjects: Leukemia, Hairy Cell; Antineoplastic Agents; Neoplasms, Second Primary; Proto-Oncogene Proteins B-raf; Cladribine; IndolesCategories: Administration & Dosage; Therapeutic Use; Drug Therapy; Epidemiology; Antagonists & Inhibitors; Diagnosis
- Calvo, Katherine R Anatomic PathologyDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.Subjects: Leukemia, Hairy Cell; Cladribine; Leukemia, Lymphocytic, Chronic, B-Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy ProtocolsCategories: Genetics; Administration & Dosage; Pathology; Therapeutic Use; Complications; Drug Therapy
- Park, Christopher Y Anatomic PathologyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Top HospitalPhysician Clinical TrialRelevant US NIH Grant Funding: $2,110,478 over the last 5 yearsMedical school: Columbia University College of Physicians and Surgeons (MD, 2001)Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 86/100Subjects: Proto-Oncogene Proteins B-raf; Leukemia, Hairy Cell; Antineoplastic Agents; Hematopoietic Stem Cells; Indoles; MutationCategories: Administration & Dosage; Genetics; Antagonists & Inhibitors; Drug Therapy; Pathology
- Gladstone, Douglas E Medical OncologyJohns Hopkins University, Baltimore, MD, USA. Top HospitalMedical school: New York University School of Medicine (MD, 1992)Medicare AcceptedDisclosed payments in 2021 from 6 biomedical companies, totalling $3,967.51, including $1,606.01 from AstraZeneca Pharmaceuticals LPSubjects: Leukemia, Hairy Cell; Antineoplastic Agents; Bacterial Toxins; Exotoxins; Neoplasm Recurrence, Local; COVID-19Categories: Therapeutic Use; Drug Therapy; Complications; Drug Effects; Therapy
- Byrd, John C HematologyThe Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH. Top HospitalMedical school: University of Arkansas College of Medicine (MD, 1991)Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 82.3/100Disclosed payments in 2021 from 3 biomedical companies, totalling $3,425.86, including $2,355 from Takeda Pharmaceuticals U.S.A., Inc.Subjects: Leukemia, Hairy Cell; Antineoplastic Agents; Pentostatin; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; FlavonoidsCategories: Therapeutic Use; Drug Therapy; Diagnosis; Pharmacology; Standards; Therapy
- Burger, Jan A Internal MedicineDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.Medical school: Other (MD, 1994)Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100Disclosed payments in 2021 from 3 biomedical companies, totalling $2,748.68, including $2,731.25 from CSL BehringSubjects: Leukemia, Hairy Cell; Antineoplastic Agents; Cladribine; Receptors, Antigen, B-Cell; Antibodies, Monoclonal, Murine-Derived; CD40 AntigensCategories: Immunology; Therapeutic Use; Pharmacology; Administration & Dosage; Drug Therapy; Pathology
- Kantarjian, Hagop M Medical OncologyDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.Disclosed payments in 2021 from 23 biomedical companies, totalling $77,883.16, including $16,295 from Amgen Inc.Subjects: Leukemia, Hairy Cell; Cladribine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational AnalysisCategories: Drug Therapy; Therapeutic Use; Administration & Dosage; Genetics; Diagnosis; Methods
- Zent, Clive S HematologyJames P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.Disclosed payments from biomedical company (AstraZeneca Pharmaceuticals LP) in 2021 for $68.97Subjects: Leukemia, Hairy Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; COVID-19; Cladribine; Cyclin D1Categories: Therapeutic Use; Administration & Dosage; Drug Therapy; Genetics; Pathology; Complications
- Wilson, Wyndham H Medical OncologyLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.Subjects: Leukemia, Hairy Cell; Bacterial Toxins; Exotoxins; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; CladribineCategories: Therapeutic Use; Drug Therapy; Administration & Dosage; Drug Effects; Immunology; Methods
- Jain, Preetesh Internal MedicineDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.Disclosed payments in 2021 from 3 biomedical companies, totalling $6,565, including $2,400 from Kite Pharma, Inc.Subjects: Leukemia, Hairy Cell; Cladribine; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; RituximabCategories: Genetics; Administration & Dosage; Drug Therapy; Therapy; Pathology; Physiopathology
- Dasanu, Constantin A Hematology & OncologyLucy Curci Cancer Center, Eisenhower Medical Center/University of Southern California, Rancho Mirage, CA, USA. Top HospitalMedical school: Other (MD, 1994)Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 84/100Disclosed payments in 2021 from 2 biomedical companies, totalling $28.99, including $17.07 from Bayer HealthCare Pharmaceuticals Inc.Subjects: Leukemia, Hairy Cell; Immune System Diseases; Neoplasms, Second Primary; Pentostatin; Adenocarcinoma; Antineoplastic AgentsCategories: Chemically Induced; Adverse Effects; Complications; Drug Therapy; Immunology; Therapeutic Use
- Kreitman, Robert JLaboratory of Molecular Biology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: .Relevant US NIH Grant Funding: $1,036,808 over the last 5 yearsSubjects: Leukemia, Hairy Cell; Bacterial Toxins; Antineoplastic Agents; Exotoxins; Cladribine; Immunoglobulin Heavy ChainsCategories: Therapeutic Use; Genetics; Drug Therapy; Metabolism; Diagnosis; Therapy
These expert listings are
for individual use without a fee. Biotechs,
Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and
other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards,
and consulting. Please contact
us for licensing, customized queries, feedback and questions.
Note:
- These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
- Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.